U.S. Markets close in 4 hrs 29 mins

Esperion Therapeutics, Inc. (ESPR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.37+1.16 (+4.43%)
As of 11:31AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close26.21
Open26.26
Bid27.18 x 1000
Ask27.27 x 1200
Day's Range26.03 - 27.51
52 Week Range23.90 - 53.73
Volume204,121
Avg. Volume812,921
Market Cap764.789M
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-5.22
Earnings DateMay 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.55
  • Esperion to Report First Quarter 2021 Financial Results May 4, 2021
    GlobeNewswire

    Esperion to Report First Quarter 2021 Financial Results May 4, 2021

    ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesday, May 4, 2021. Following the release, company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and business progress. The call can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing the access code 6373518. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion Therapeutics ESPERION is The Lipid Management Company. Our goal is lipid management for everybody, that’s why we work hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc. ESPERION Therapeutics’ Commitment to Patients with Hyperlipidemia High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading to cardiovascular events, including heart attack and stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C. There are approximately 18 million people in the U.S. living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy — including individuals considered statin averse — leaving them at high risk for cardiovascular events1. In the United States, more than 50 percent of atherosclerotic cardiovascular disease (ASCVD) patients and heterozygous familial hypercholesterolemia (HeFH) patients who are not able to reach their guideline recommended LDL-C levels with statins alone need less than a 40 percent reduction to reach their LDL-C threshold goal2. ESPERION's mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide the additional LDL-C lowering that these patients need. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding commercialization plans for bempedoic acid tablet and the bempedoic acid/ezetimibe fixed dose combination tablet. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion’s clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, the impact of COVID-19 on our business, clinical activities and commercial development plans, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. References (1) ESPERION market research on file: research project interviewing 350 physicians. ESPERION Therapeutics, Inc. Sept-Oct 2018. (2) Data on file: analysis of NHANES database. ESPERION Therapeutics, Inc. 2018. Investor Contact:Kaitlyn BroscoEsperioncorporateteam@esperion.com

  • Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
    GlobeNewswire

    Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference

    ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 9:30 a.m. Eastern Time. Event: 20th Annual Needham Virtual Healthcare ConferenceDate:April 13, 2021Format:Fireside chat & 1:1 Investor meetingsTime:9:30 a.m. ET A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replay of the webcast will be archived on the Company's website for 90 days following the event. Esperion Therapeutics Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc. Esperion Therapeutics’ Commitment to Patients with Hyperlipidemia High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading to cardiovascular events, including heart attack and stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C. There are approximately 18 million people in the U.S. living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy — including individuals considered statin averse — leaving them at high risk for cardiovascular events1. In the United States, more than 50 percent of atherosclerotic cardiovascular disease (ASCVD) patients and heterozygous familial hypercholesterolemia (HeFH) patients who are not able to reach their guideline recommended LDL-C levels with statins alone need less than a 40 percent reduction to reach their LDL-C threshold goal2. Esperion's mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide the additional LDL-C lowering that these patients need. References(1) Esperion market research on file: research project interviewing 350 physicians. Esperion Therapeutics, Inc. Sept-Oct 2018.(2) Data on file: analysis of NHANES database. Esperion Therapeutics, Inc. 2018. Investor Contact:Kaitlyn BroscoEsperioncorporateteam@esperion.com

  • Is It Too Late to Buy Esperion Therapeutics (ESPR) Stock?
    Insider Monkey

    Is It Too Late to Buy Esperion Therapeutics (ESPR) Stock?

    Wasatch Micro Cap Value Fund recently released its Q4 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 26.1% for the quarter, underperforming its benchmark, the Russell Microcap Index which returned 31.4% in the same quarter. You should check out Wasatch’s top 5 stock picks for investors […]